Evogene Ltd. - Ordinary Shares (EVGN): Price and Financial Metrics

Evogene Ltd. - Ordinary Shares (EVGN): $0.58

0.00 (0.76%)

POWR Rating

Component Grades








Add EVGN to Watchlist
Sign Up

Industry: Agriculture




#29 of 33

in industry

EVGN Price/Volume Stats

Current price $0.58 52-week high $1.30
Prev. close $0.58 52-week low $0.55
Day low $0.58 Volume 48,700
Day high $0.62 Avg. volume 82,731
50-day MA $0.61 Dividend yield N/A
200-day MA $0.74 Market Cap 23.96M

EVGN Stock Price Chart Interactive Chart >

EVGN Stock Summary

  • With a price/sales ratio of 12.9, EVOGENE LTD has a higher such ratio than 91.63% of stocks in our set.
  • With a year-over-year growth in debt of 377.28%, EVOGENE LTD's debt growth rate surpasses 96.01% of about US stocks.
  • Revenue growth over the past 12 months for EVOGENE LTD comes in at 149.28%, a number that bests 95.67% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to EVOGENE LTD are HYLN, VTGN, MEIP, HIMX, and DBVT.
  • Visit EVGN's SEC page to see the company's official filings. To visit the company's web site, go to www.evogene.com.

EVGN Valuation Summary

  • In comparison to the median Healthcare stock, EVGN's EV/EBIT ratio is 105.83% lower, now standing at -0.7.
  • Over the past 126 months, EVGN's price/earnings ratio has gone up 88.6.

Below are key valuation metrics over time for EVGN.

Stock Date P/S P/B P/E EV/EBIT
EVGN 2023-05-23 12.9 1.2 -1.1 -0.7
EVGN 2023-05-22 12.9 1.2 -1.1 -0.7
EVGN 2023-05-19 11.9 1.1 -1.0 -0.6
EVGN 2023-05-18 12.4 1.2 -1.0 -0.7
EVGN 2023-05-17 16.2 1.0 -1.0 -0.4
EVGN 2023-05-16 16.0 1.0 -1.0 -0.4

EVGN Growth Metrics

    Its 5 year cash and equivalents growth rate is now at 859.27%.
  • The 4 year net cashflow from operations growth rate now stands at -22.61%.
  • Its 2 year revenue growth rate is now at 73.75%.
EVGN's revenue has moved down $3,919,000 over the prior 67 months.

The table below shows EVGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.326 -29.503 -31.011
2022-06-30 1.011 -28.257 -32.077
2022-06-30 1.011 -28.257 -32.077
2022-03-31 0.834 -27.734 -29.466
2021-12-31 0.93 -24.716 -27.793
2021-12-31 0.93 -24.839 -27.793

EVGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EVGN has a Quality Grade of D, ranking ahead of 9.47% of graded US stocks.
  • EVGN's asset turnover comes in at 0.015 -- ranking 85th of 89 Chemicals stocks.
  • 500 - Internal server error

The table below shows EVGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.015 0.448 -2.136
2019-12-31 0.012 0.556 -0.546
2018-12-31 0.026 0.169 -0.317
2017-12-31 0.039 0.159 -0.253
2016-12-31 0.063 0.138 -0.203
2015-12-31 0.093 0.258 -0.146

EVGN Price Target

For more insight on analysts targets of EVGN, see our EVGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.50 Average Broker Recommendation 1.5 (Moderate Buy)

Evogene Ltd. - Ordinary Shares (EVGN) Company Bio

Evogene Ltd. operates as a plant genomics company that uses a technology infrastructure to enhance seed traits underlying crop productivity. The company was founded in 1999 and is based in Rehovot, Israel.

EVGN Latest News Stream

Event/Time News Detail
Loading, please wait...

EVGN Latest Social Stream

Loading social stream, please wait...

View Full EVGN Social Stream

Latest EVGN News From Around the Web

Below are the latest news stories about EVOGENE LTD that investors may wish to consider to help them evaluate EVGN as an investment opportunity.

Lavie Bio Receives Canadian Regulatory Approval for Thrivus™, Expanding Global Reach

Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), and a leading ag-biological company focusing on improving food quality, sustainability, and agricultural productivity through the introduction of microbiome-based products, today announced it had received registration for Thrivus™ from The Canadian Food Inspection Agency (CFIA), which triples the product's sales territory. Thrivus™, a bio-inoculant seed treatment, increases Hard Red Spring Wheat production by increasing th

Yahoo | May 24, 2023

Evogene (EVGN) Reports Q1 Loss, Misses Revenue Estimates

Evogene (EVGN) delivered earnings and revenue surprises of 6.25% and 26.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 18, 2023

Evogene Reports First Quarter 2023 Financial Results

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the first quarter period ending March 31, 2023.

Yahoo | May 18, 2023

Evogene Ag-Seed Division Awarded Prestigious €1.2M Horizon Grant to Develop Oil-Seed Crops with High CO2 Assimilation and Drought Tolerance

The Ag-Seed Division of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) ("Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments has announced that it has been granted a prestigious EU Horizon grant of €1.2 million, to support the creation of oil-seed crops that have high carbon-dioxide assimilation and enhanced drought tolerance. The project, Crop4Clima, has an overall budget of €2.5 million and is ex

Yahoo | May 9, 2023

Evogene Schedules First Quarter 2023 Financial Results Release & Conference Call for May 18, 2023

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development, announced today that it will release its financial results for the first quarter of 2023, on Thursday, May 18, 2023.

Yahoo | May 4, 2023

Read More 'EVGN' Stories Here

EVGN Price Returns

1-mo -4.45%
3-mo -13.43%
6-mo -12.25%
1-year -36.61%
3-year -50.60%
5-year -82.37%
YTD -17.14%
2022 -57.32%
2021 -65.11%
2020 209.21%
2019 -23.23%
2018 -35.50%

Continue Researching EVGN

Want to see what other sources are saying about Evogene Ltd's financials and stock price? Try the links below:

Evogene Ltd (EVGN) Stock Price | Nasdaq
Evogene Ltd (EVGN) Stock Quote, History and News - Yahoo Finance
Evogene Ltd (EVGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!